True DX in the Pharma R&D Lab Defined by Enthought

Enthought’s team in Japan exhibited at the Pharma IT & Digital Health Expo 2022 life sciences conference in Tokyo, to meet with pharmaceutical industry leaders gathering for technological insight and to revitalize market growth. 200 companies exhibited across the 3-day in-person event, which drew over 6,700 attendees.

With digital transformation a headline theme, the show offered a great opportunity to engage with our target audience and showcase Enthought innovations that are accelerating novel discovery in the pharmaceutical industry.

We were honored to have Mr. Atsushi Hyogo of Daiichi Sankyo with us to present with Enthought’s Senior Executive, Dai Ike. Mr. Hyogo presented real world applications of digital transformation realized with Enthought technology and deep scientific expertise. He showed that true DX—and partnering with Enthought—is empowering faster scientific discovery and continuous innovation at Daiichi Sankyo and supporting their 2030 vision to transition a data-driven model of management.

Dai Ike framed the true value of digital transformation that Enthought brings to customers across Japan.

Our work makes it possible for scientists to expand the capacity of their work within their companies because we concentrate on three critical areas of improvement: process, technology, and people.

Altogether, Enthought changes the workflow and eases the workload within R&D labs, allowing iterations of testing to continuously be brought into analysis and lead to faster drug discovery.

Daiichi Sankyo, one of the top twenty pharmaceutical manufacturers worldwide, has experienced game-changing results by partnering with Enthought to transform R&D. Mr. Hyogo, former Director of Oncology, led the way in establishing change that pushed his lab into a higher range of performance. Sensing an impending crisis and the danger of falling behind the market, Daiichi Sankyo began a DX initiative, but they knew that they needed support from an experienced partner, and Enthought met all the qualities they sought. “Enthought is clearly the best DX partner for us because they are both technologists and scientists, and they have experience in the life sciences domain,” stated Mr. Hyogo.

DX is a core theme at the moment in Japan, and it has taken on urgency in pharmaceuticals that is unparalleled in other industries. As companies are evolving through similar problems, they face misunderstandings of DX by top management. DX is much more than commonly thought. It goes far beyond digitizing and organizing data to connect scientists with technologies for automating iterative testing and analysis. Most companies have no idea where or how to start. At Enthought, we are encouraged by how eager companies are to start on a DX journey and we have a program to jumpstart the work together.

True DX addresses the business ecosystem, and starts with the scientists in the R&D lab.

Enthought occupies a valuable and unique role in the DX conversation. Many companies use the term DX when they talk about shifting the traditional business relationships over to new platforms or applications, such as connecting patients and doctors through mobile technology, developing social media for healthcare companies, or new health management systems. We deliver change at the level of science. We change the way companies are doing science.

There are opportunities to continue to expand in the area of life sciences in Japan and deliver value to companies that struggle with the many demands for DX and are seeking one, reliable and proven partner, such as Enthought.

Contact us to learn more.

Share this article:

Related Content

True DX in the Pharma R&D Lab Defined by Enthought

Enthought’s team in Japan exhibited at the Pharma IT & Digital Health Expo 2022 life sciences conference in Tokyo, to meet with pharmaceutical industry leaders…

Read More

Life Sciences Labs Optimize with New Digital Technologies and Upskilling

Labs are resetting the trajectory for drug development: reducing timelines from years to months; decreasing costs from billions to millions; and gaining an advantage by…

Read More

Digital Transformation of the Materials Science R&D Lab

“Digital transformation”, “machine learning”, and “artificial intelligence” are buzzwords heard in every industry, from the boardroom to the lab. We asked Dr. Michael Heiber, lead…

Read More

A Beginner’s Guide to Deep Learning

Deep learning. By this point, we’ve all heard of it. It’s the magic silver bullet that can fix any complex problem. It’s the special ingredient…

Read More

Webinar Q&A: Accelerating Product Reformulation with Machine Learning

In our recent C&EN Webinar: Accelerating Consumer Products Reformulation with Machine Learning, we demonstrated how to leverage digital tools and technology to bring new products…

Read More

Scientists Who Code

Digital skills personas for success in digital transformation The digital skills mix varies widely across companies, from those just starting to invest in digital transformation…

Read More

The Challenges of Scaling Digital Advances in Life Sciences

Scaling innovations in R&D can be considered challenging in two dimensions: from lab to lab; and from the lab to the end customer. A 100x…

Read More

Digital Transformation in Practice

Taken from the webinar, the frequent strategy of digitalization-layering digital tools and technology onto existing processes-provides incremental value, which soon flattens out. At the other…

Read More

Giving Visibility to Renewable Energy

The ultimate project goal of EnergizAIR Infrastructure was to raise individual awareness of the contribution of renewable energy sources, and ultimately change behaviors. Now ten…

Read More

Machine Learning in Materials Science

The process of materials discovery is complex and iterative, requiring a level of expertise to be done effectively. Materials workflows that require human judgement present…

Read More

Join Our Mailing List!

Sign up below to receive email updates including the latest news, insights, and case studies from our team.